Results 91 to 100 of about 174,356 (352)

Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients

Journal of Oncological Sciences
Objective: Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality, with rat sarcoma (RAS) and proto-oncogene B-raf (BRAF) mutations associated with worse prognosis in metastatic settings.
Alper TOPAL, Goncagül AKDAĞ, Ayşegül DUMLUDAĞ, Çağlar KÖSEOĞLU, Ömer Faruk KUZU, Hüseyin ATACAN, Baran Can AYTAÇ, Gizem YILDIRIM, Sedat YILDIRIM, Hacer Şahika YILDIZ, Gülsema YILDIRAN KESKİN, Nuri KARADURMUŞ   +11 more
doaj   +1 more source

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition

JCO Precision Oncology, 2020
PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with
Nobre L., Zapotocky M., Ramaswamy V., Ryall S., Bennett J., Alderete D., Guill J. B., Baroni L., Bartels U., Bavle A., Bornhorst M., Boue D. R., Canete A., Chintagumpala M., Coven S. L., Cruz O., Dahiya S., Dirks P., Dunkel I. J., Eisenstat D., Conter C. F., Finch E., Finlay J. L., Frappaz D., Garre M. L., Gauvain K., Bechensteen A. G., Hansford J. R., Harting I., Hauser P., Hazrati L. -N., Huang A., Injac S. G., Iurilli V., Karajannis M., Kaur G., Kyncl M., Krskova L., Laperriere N., Larouche V., Lassaletta A., Leary S., Lin F., Mascelli S., McKeown T., Milde T., la Madrid A. M., Morana G., Morse H., Mushtaq N., Osorio D. S., Packer R., Pavelka Z., Quiroga-Cantero E., Rutka J., Sabel M., Salgado D., Solano P., Sterba J., Su J., Sumerauer D., Taylor M. D., Toledano H., Tsang D. S., Fernandes M. V., van Landeghem F., van Tilburg C. M., Wilson B., Witt O., Zamecnik J., Bouffet E., Hawkins C., Tabori U.   +72 more
openaire   +7 more sources

Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage‐Induced Mitochondrial Apoptosis and Parthanatos‐Like Cell Death

Advanced Science, EarlyView.
Homoisoflavanone (HIF), a bioactive compound isolated from Polygonatum kingianum, selectively suppresses colorectal cancer progression by inducing DNA damage‐mediated mitochondrial apoptosis and parthanatos‐like cell death. HIF triggers mitochondrial dysfunction, including depolarized membrane potential, elevated ROS, and ATP depletion, while impairing
Hongjie Fan, Huzi Zhao, Pei Zhang, Pengfei Yu, Yunfei Ji, Gang Chen, Hongli Jin, Yanfang Liu, Jin Liu, Zhe‐Sheng Chen, Aiping Lyu, Xinmiao Liang, Yang Chen   +12 more
wiley   +1 more source

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

Advanced Science, EarlyView.
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu, Muhammad Aminu, Pingjun Chen, Jian‐Rong Li, Chuanpeng Dong, Chenyang Li, Yanhua Tian, Shao‐Wei Lu, Hong Chen, Chenxi Ma, Xin Hu, Jie Ye, Andrew Y. Liu, Beibei Huang, Frank R. Rojas, Parra Cuentas. Edwin Roger, Ou Shi, Monique B. Nilsson, Alissa Poteete, Khaja B. Khan, Wei Lu, Luisa M. Solis Soto, Junya Fujimoto, Cara Haymaker, Ignacio I. Wistuba, Zhubo Wei, Linghua Wang, Don L. Gibbons, Ken Chen, Alexandre Reuben, Jason M. Schenkel, John V. Heymach, Chao Cheng, Jia Wu, Jianjun Zhang   +34 more
wiley   +1 more source

Meta-analysis of clinical trials on concordance of mutational stauts of primary tumour and distant metastases of colorectal cancer

Тазовая хирургия и онкология, 2017
Background. During the last years several trials emerged demonstrating high tumour heterogeneity, including those on colorectal cancer.Objective. These findings made us initiate a meta-analysis of trials dedicated to this question.Materials and methods ...
M. Yu. Fedyanin, A. A. Tryakin, I. A. Pokataev, S. A. Tyulyandin   +3 more
doaj   +1 more source

BRAF NM_004333.4:c.1397G>T [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Real‐Time Visualization of Isoform‐Specific RAF‐KRAS Interactions in Living Cells Using FRET‐BRET Hybrid Biosensors

Advanced Science, EarlyView.
Hybrid FRET–BRET biosensors were developed to monitor RAF–KRAS interactions in living cells. These sensors enable real‐time visualization of interaction dynamics, quantitative spectral analysis, and validation of mutation‐selective inhibitors, providing a versatile platform for probing KRAS regulation and therapeutic responses. ABSTRACT The RAS–RAF–MEK–
Jeong‐Min Go, Dahee Lee, Minji Kim, Kiseok Han, Gyuho Choi, ChanHui Song, Sanghyun Ahn, Yerim Lee, Jinyoung Lee, Yingxiao Wang, Jung‐Soo Suh, Hwayoung Yun, Tae‐Jin Kim   +12 more
wiley   +1 more source

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. [PDF]

, 2015
BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who ...
Cronin, Maureen T, Falchook, Gerald, Hong, David, Hwu, Patrick, Kim, Kevin B, Kurzrock, Razelle, Stephens, Philip J, Tsimberidou, Apostolia M, Wheler, Jennifer, Yelensky, Roman   +9 more
core   +3 more sources

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Oncotarget, 2014
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients develop
SPAGNOLO, FRANCESCO, GHIORZO, PAOLA, Queirolo, P.   +2 more
openaire   +3 more sources